Tigecycline: a critical safety review

  title={Tigecycline: a critical safety review},
  author={Quanhathai Kaewpoowat and Luis Ostrosky-Zeichner},
  journal={Expert Opinion on Drug Safety},
  pages={335 - 342}
Introduction: The emergence of multidrug-resistant (MDR) infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline, a broad spectrum antibiotic covering against many MDR organisms, has been widely used. However, recent meta-analysis studies have raised a concern for its efficacy and safety. Reviewing tigecycline safety data would enhance the appropriate use of this medication. Areas covered: This article reviews the safety profile of… 

Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections

The availability of new drugs showing a potent in vitro activity against CR-GNB represents a unique opportunity to face the threat of resistance, while potentially reducing toxicity.

Re-defining tigecycline therapy.

Patients who may be treated with monotherapy, according to the official indications and dosages, from those treated with combination treatment, mostly with high dosages in the setting of nosocomial IAIs, possibly caused by MDR bacteria or as a carbapenem-sparing strategy are distinguished.

Safety considerations of current drug treatment strategies for nosocomial pneumonia

The safety profiles of the most common antimicrobials for treating nosocomial pneumonia are analyzed, and linezolid seems to be the superior option for treating methicillin-resistant Staphylococcus aureus.

Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

Tigecycline showed in vitro susceptibility to Coxiella spp, Rickettsia spp.

Tigecycline: Role in the Management of cIAI and cSSTI in the Indian Context

Tigecycline can be a good alternative in MDR and XDR complicated intra-abdominal and complicated skin and soft tissue infections and has potent in vitro activity against Gram-negative carbapenemase producers, except Pseudomonas aeruginosa and Proteus spp.

Safety considerations with new antibacterial approaches for chronic bacterial prostatitis

Most antibacterial agents considered in this review have been administered off-label in the interest of patients, and their use requires particular caution, so readers should be warned of the limited published evidence supporting therapy for CBP with these agents.

Delirium induced by tigecycline treatment for Acinetobacter baumannii infection

This work presents what it believes to be the first case of tigecycline-induced delirium, a 77-year-old male patient with end-stage renal disease who was hospitalized due to acute exacerbation of chronic obstructive pulmonary disease, and advises clinicians to be aware of this potential adverse effect of tIGecYcline.

An update on emerging therapies for urinary tract infections

This review summarized data on already approved antibiotics, and selected emerging therapies that are currently in phase II and III trials with emphasis on complicated urinary tract infections (cUTIs), and selected dugs in initial and later stages of development.

Carbapenem-Resistant Gram-Negative Bacterial Infections in Children

A comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children, which includes epidemiology, risk factors, outcomes, and antimicrobial therapy management, with particular attention being given to new antibiotics.

Optimal tigecycline dosage regimens in patients infected with carbapenem-resistant Enterobacteriaceae

Tigecycline seems to be a possible treatment for CRE; however, tigecYcline 200 mg daily may be optimized to cover the CRE isolates with a MIC ≤ 1 µg/mL.



Tigecycline: an update.

Effectiveness and safety of tigecycline: focus on use for approved indications.

Tigecycline was not associated with higher mortality than comparator antibiotics in patients with infections for which there is approval for its use and was as effective as comparators for the treatment of patients with infection that are approved indications for the use of the drug.

Efficacy and safety of tigecycline: a systematic review and meta-analysis.

Clinicians should avoid tigecycline monotherapy in the treatment of severe infections and reserve it as a last-resort drug.

Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease

Evidence is provided that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE, and prudence with the clinical use of tigECyclines monotherapy in infections is required.

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

It is demonstrated that tigecycline was efficacious and well tolerated in the treatment of patients with complicated intra-abdominal infections and microbiological modified intent-to-treat populations.

Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies.

Excretion of Antimicrobials Used to Treat Methicillin‐Resistant Staphylococcus aureus Infections During Lactation: Safety in Breastfeeding Infants

Although the risk to infants seems to be relatively low for most of the agents explored, the paucity of data indicates a need for close monitoring of breastfed infants whose mothers are receiving an antibiotic for an MRSA skin and soft tissue infection.